Sabra Health Care REIT, Inc. (SBRA) Cash Flow Statement

The reported AFFO series shows that the dividend is covered in some quarters with thin margin and not covered in others, which suggests distributions may have been funded partly from balance sheet resources or other sources during weaker periods. Investors should monitor whether the 2026Q2 shortfall reflects timing of recurring capital items or a more structural erosion of distributable cash. The absence of AFFO data for several quarters limits confidence in a full trend assessment.

The wide swings in the FFO-to-net-income ratio indicate that GAAP earnings are a poor proxy for the cash generated by the real estate base. Operating cash flow of $129.0M in 2026Q3 and $85.8M in 2026Q2 suggests cash conversion is steadier than net income, though lumpy. Analysts should anchor on FFO and AFFO rather than headline net income when assessing cash earning power.

This gap suggests that sustaining distributions during any quarter of weak AFFO would likely require external capital, revolver draws, or asset sales, though the filings provided do not disclose specific facility availability. The 0.90% debt-to-equity figure appears anomalous for a REIT and warrants verification against SEC filings before drawing firm conclusions about leverage capacity. Investors should watch for any reliance on equity issuance to bridge distribution shortfalls.

The pattern suggests capital spending is episodic rather than smooth, and the zero-capex quarters may reflect timing of recognition rather than an absence of maintenance needs. Free cash flow margins of 45.3% in 2026Q3 versus 25.7% in 2026Q2 are therefore partly a function of this lumpiness. Analysts should normalize capex across a trailing period before comparing FCF margins to peers such as OHI or CTRE.